Abstract
Since Alzheimer disease (AD) is a multifactorial disease, recent therapeutical approaches concentrate on the development of a multitargeting drug. Various protein kinases are known to be involved in the progression of AD. A first series of 3-ethoxycarbonyl-1-aza-9-oxafluorenes has been synthesized and biologically evaluated as AD-relevant protein kinase inhibitors. A concentration-dependent inhibition of important AD-relevant kinases has been characterized after the selectivity of kinase inhibition had been demonstrated. Structure-activity relationships of protein kinase inhibition are discussed and first multitargeting inhibitors have been identified.
Keywords: Multitargeting, structure-activity relationships, biological activity, alzheimer disease, compound profiling, protein kinases.
Medicinal Chemistry
Title:Approaches to a Multitargeting Drug Development: First Profiled 3- Ethoxycarbonyl-1-aza-9-oxafluorenes Representing a Perspective Compound Class Targeting Alzheimer Disease Relevant Kinases CDK1, CDK5 and GSK-3β
Volume: 10 Issue: 1
Author(s): Andreas Hilgeroth, Volkmar Tell, Steffi Kramer, Frank Totzke and Christoph Schachtele
Affiliation:
Keywords: Multitargeting, structure-activity relationships, biological activity, alzheimer disease, compound profiling, protein kinases.
Abstract: Since Alzheimer disease (AD) is a multifactorial disease, recent therapeutical approaches concentrate on the development of a multitargeting drug. Various protein kinases are known to be involved in the progression of AD. A first series of 3-ethoxycarbonyl-1-aza-9-oxafluorenes has been synthesized and biologically evaluated as AD-relevant protein kinase inhibitors. A concentration-dependent inhibition of important AD-relevant kinases has been characterized after the selectivity of kinase inhibition had been demonstrated. Structure-activity relationships of protein kinase inhibition are discussed and first multitargeting inhibitors have been identified.
Export Options
About this article
Cite this article as:
Hilgeroth Andreas, Tell Volkmar, Kramer Steffi, Totzke Frank and Schachtele Christoph, Approaches to a Multitargeting Drug Development: First Profiled 3- Ethoxycarbonyl-1-aza-9-oxafluorenes Representing a Perspective Compound Class Targeting Alzheimer Disease Relevant Kinases CDK1, CDK5 and GSK-3β , Medicinal Chemistry 2014; 10 (1) . https://dx.doi.org/10.2174/157340641001131226141606
DOI https://dx.doi.org/10.2174/157340641001131226141606 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design Simulation and Performance Analysis of Tilted Time Window and Support Vector Machine Based Learning Object Ranking Method
Recent Advances in Electrical & Electronic Engineering Transglutaminase-Catalyzed Crosslinking in Neurological Disease: From Experimental Evidence to Therapeutic Inhibition
CNS & Neurological Disorders - Drug Targets Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimers Disease
Current Pharmaceutical Design The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry
Current Drug Metabolism Up-regulation of DMN Connectivity in Mild Cognitive Impairment Via Network-based Cognitive Training
Current Alzheimer Research Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Towards Practical Cognitive Assessment for Detection of Early Dementia: A 30-Minute Computerized Battery Discriminates as Well as Longer Testing
Current Alzheimer Research Subtype Classification by Polymerase and Gag Genes of HIV-1 Iranian Sequences Registered in the NCBI GenBank
Current Proteomics Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology
Current Pharmaceutical Design Running Exercise Reduces Myelinated Fiber Loss in the Dentate Gyrus of the Hippocampus in APP/PS1 Transgenic Mice
Current Alzheimer Research Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Current Hypertension Reviews Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Current Genomics Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Editorial [Hot Topic: Oxidative Stress Induced-Metabolic Imbalance, Mitochondrial Failure, And Cellular Hypoperfusion As Primary Pathogenetic Factors For The Development Of Alzheimer Disease Which Can Be Used As An Alternate And Successful Drug Treatment Strategy: Past, Present And Future (Guest Editor: Gjumrakch Aliev)]
CNS & Neurological Disorders - Drug Targets